CD274 and neoplasm: Combination strategies with other anti-tumor agents to potentiate the efficacy of anti-PD-L1/anti-PD-1 in patients with pMMR/MSS advanced or metastatic CRC has become a major research interest as it provides new therapeutic opportunities.